Tissue repair and regeneration are complex natural processes that involve multiple types of cells and signaling molecules. In normal undamaged tissues these signals are used only for replacement of aging cells. Following tissue injury, ischemia, or vascular damage (including that which is caused by radiation exposure) progenitor stem cells can be activated to restore tissue function. In aging adults, and those with many common diseases, these cells or the signals that activate them are lost or diminished.
With vascular damage, thrombin is released to form blood clots and prevent blood loss. A portion of this same thrombin molecule that includes the TP508 peptide sequence is released to initiate repair by activating endothelial cells and recruiting stem/progenitor cells to the site of injury.
Studies show that TP508 protects and activates stem cells in multiple organs
Chrysalis BioTherapeutics is harnessing this natural regenerative process using TP508 related molecules to switch on cellular responses to protect tissues and accelerate revascularization and repair. TP508 binds receptors expressed on the surface of endothelial cells, stem cells, and certain inflammatory cells involved in tissue repair. Upon binding to these receptors, TP508 activates a signaling cascade that restores vascular function in endothelial cells, stimulates proliferation and mobilization of progenitor stem cells, and reduces inflammation.
Extensive research has shown that TP508:
- Activates neural stem cells in the hippocampus of the brain to restore neurocognitive function and decrease mental decline following whole brain radiation
- Decreases neural inflammation that leads to neural degeneration following radiation, traumatic brain injury, and neurodegenerative diseases
- Activates stem cells in bone marrow, skin, and intestinal mucosa to mitigate damaging effects of radiation exposure, ischemia, traumatic injury and disease.